Diabetes Management Market, Worldwide, 2005-2015

Table of Contents

EXECUTIVE SUMMARY

• Some Diabetes Basics
• A Large and Growing Market
• A Many-Sided Market
• Pharmaceuticals for Diabetes
• Insulin
• Oral Anti-diabetic Drugs
• The Pharmaceutical Diabetes Market
• Insulin Administration Devices
• Medical Devices for Diabetes
• Total Diabetes Market
• Regional Segmentation
• Market Growth
• The Diabetes Industry
• Pharmaceutical Companies
• Medical Device Companies

SECTION 1: ABOUT DIABETES

• 1.1 What is Diabetes?
• 1.2 Blood Sugar Regulation
  • 1.2.1 Insulin
• 1.3 Main Types of Diabetes
  • 1.3.1 Type 1 Diabetes
  • 1.3.2 Type 2 Diabetes
  • 1.3.3 Gestational Diabetes
  • 1.3.4 Obesity-Related type 2 Diabetes in Children.
  • 1.3.5 Mature-onset Diabetes of the Young (MODY)
  • 1.3.6 Other Diabetic States
• 1.4 Diagnosis
  • 1.4.1 Glucose Tests
  • 1.4.2 Official Criteria
  • 1.4.3 Differential Diagnosis
    • 1.4.3.1 Type 1 Diabetes
    • 1.4.3.2 Type 2 Diabetes
• 1.5 Current Treatment
  • 1.5.1 Type 1 Diabetes
  • 1.5.2 Type 2 Diabetes
  • 1.5.3 Diet
• 1.6 Future Treatment Approaches
• 1.7 Treatment Monitoring
  • 1.7.1 Blood Sugar Control
  • 1.7.2 The Diabetes Control and Complications Trial
  • 1.7.3 Glycated haemoglobin (HbA1c)
  • 1.7.4 Fructosamine
• 1.8 Incidence and Prevalence of Diabetes
  • 1.8.1 Worldwide
    • 1.8.1.1 Type 1
    • 1.8.1.2 Type 2
  • 1.8.2 USA
    • 1.8.2.1 Type 1
    • 1.8.2.2 Type 2
  • 1.8.3 Japan
    • 1.8.3.1 Type 1
    • 1.8.3.2 Type 2
  • 1.8.4 Europe
    • 1.8.4.1 Type 1
    • 1.8.4.2 Type 2
• 1.9 Diabetic Complications
  • 1.9.1 Retinopathy
  • 1.9.2 Neuropathy
  • 1.9.3 Nephropathy
• 1.10 Metabolic Syndrome

SECTION 2: PRODUCTS USED IN DIAGNOSIS AND MONITORING

• 2.1 Blood Glucose Monitoring Devices: Suppliers and Products
  • 2.1.1 Lancets
  • 2.1.2 Blood Sampling Devices
    • 2.1.2.1 Bayer Diagnostics
    • 2.1.2.2 Becton Dickinson
    • 2.1.2.3 Cell Robotics
    • 2.1.2.4 LifeScan
    • 2.1.2.5 Roche Diagnostics
  • 2.1.3 Blood Glucose Monitors
    • 2.1.3.1 77 Elektronica Kft
    • 2.1.3.2 Abbott Laboratories
    • 2.1.3.3 Acon Laboratories Inc.
    • 2.1.3.4 Apex Biotechnology Corp.
    • 2.1.3.5 Bayer Corporation
    • 2.1.3.6 Becton Dickinson & Co
    • 2.1.3.7 Belbiosens
    • 2.1.3.8 Cygnus Inc -- Animas Corp
    • 2.1.3.9 Diagnostic Devices Inc.
    • 2.1.3.10 Eumed Biotechnology Co. Ltd.
    • 2.1.3.11 HMD Bio Medical
    • 2.1.3.12 Glucoplus Inc
    • 2.1.3.13 HemoCue AB
    • 2.1.3.14 Home Diagnostics Inc
    • 2.1.3.15 Hypoguard
    • 2.1.3.16 LifeScan Inc
    • 2.1.3.17 Medtronic MiniMed
    • 2.1.3.18 Polymer Technology Systems Inc.
    • 2.1.3.19 QuestStar Medical Inc
    • 2.1.3.20 Roche
    • 2.1.3.21 TaiDoc Technology Corporation
    • 2.1.3.22 US Diagnostics Inc.
  • 2.1.4 New Developments in Glucose Testing
• 2.2 'Artificial Pancreas'
  • 2.2.1 Medtronic
  • 2.2.2 Roche
  • 2.2.3 Abbott
  • 2.2.4 Novo Nordisk/LifeScan
• 2.3 Other Testing Approaches
  • 2.3.1 Haemoglobin A1c
    • 2.3.1.1 Hemoglobin A1c Meters
    • 2.3.1.2 Hemoglobin A1c Kits
• 2.4 Software Programs for Diabetes Monitoring.
  • 2.4.1 Web Software
  • 2.4.2 Commercial Software

SECTION 3: PRODUCTS USED IN TREATMENT

• 3.1 Insulin
  • 3.1.1 History
    • 3.1.1.1 Bovine and Porcine Insulin
    • 3.1.1.2 Humanized Insulin
  • 3.1.2 Companies Supplying Insulin
    • 3.1.2.1 Eli Lilly
    • 3.1.2.2 Aventis
    • 3.1.2.3 Novo Nordisk
    • 3.1.2.4 Some Other Suppliers
  • 3.1.3 Insulin Delivery
    • 3.1.3.1 Syringes
  • 3.1.4 Insulin Syringe Manufacturers
    • 3.1.4.1 Pens
    • 3.1.4.2 Manufacturers of Insulin Pens
    • 3.1.4.3 Injectors
    • 3.1.4.4 Injector Manufacturers
  • 3.1.5 Inhaled insulin
  • 3.1.6 Pfizer/Sanofi-Aventis/Nektar Therapeutics
    • 3.1.6.1 Lilly/Alkermes
    • 3.1.6.2 Novo Nordisk/Aradigm
    • 3.1.6.3 MannKind
  • 3.1.7 Insulin Pumps
    • 3.1.7.1 What is an Insulin Pump?
    • 3.1.7.2 The Infusion Set
    • 3.1.7.3 Candidates for Pump Therapy
  • 3.1.8 Companies Supplying Insulin Pumps
    • 3.1.8.1 Animas Corporation
    • 3.1.8.2 DANA Diabecare
    • 3.1.8.3 Medtronic MiniMed
    • 3.1.8.4 Nipro Diabetes Systems
    • 3.1.8.5 Roche Disetronic
    • 3.1.8.6 Smiths Medical
• 3.2 Oral Hypoglycaemic Drugs
  • 3.2.1 Sulfonylureas
  • 3.2.2 Biguanides
  • 3.2.3 Alpha-Glucosidase Inhibitor
  • 3.2.4 Thiazolidinediones
  • 3.2.5 Prandial Glucose Regulators
  • 3.2.6 Incretin Mimetics
  • 3.2.7 Amylin Mimetic
  • 3.2.8 New Products Now in R&D

SECTION 4: NOVEL APPROACHES TO DIABETES MANAGEMENT

• 4.1 Pancreas Transplants
• 4.2 Islet Cell Transplants
  • 4.2.1 Edmonton Protocol
  • 4.2.2 Improving ICT
  • 4.2.3 Living-Donor Islet Cell Transplant
• 4.3 Stem Cell Developments
  • 4.3.1 ADA Endorsement
  • 4.3.2 Stem Cell Research at EASD 2005
  • 4.3.2.1 Adult Stem Cells
• 4.4 Antibody Treatment
• 4.5 Vaccines
  • 4.5.1 Diamyd Medical
  • 4.5.2 DeveloGen
• 4.6 Genetic Approaches
  • 4.6.1 Genetic Testing
  • 4.6.2 Small-interfering RNA (SiRNA)
• 4.7 Novel Drugs
  • 4.7.1 DDP-IV Inhibitors
  • 4.7.2 Other Drugs
  • 4.7.3 All-in-one Treatment for Type 2 Diabetes?
• 4.8 Continuous Glucose Monitoring
  • 4.8.1 Electroenzymatic Sensor
  • 4.8.2 Optical Glucose Sensor
  • 4.8.3 Sensor Based on Carbon Nanotubes

SECTION 5: THE DIABETES MARKET

• 5.1 Global Market
  • 5.1.1 Size
  • 5.1.2 Growth
  • 5.1.3 Regional Segmentation
• 5.2 Market Analysis by Product Category
  • 5.2.1 Monitoring Products
    • 5.2.1.1 Major Suppliers
  • 5.2.2 Insulins and Insulin Delivery Devices
    • 5.2.2.1 Major Suppliers
  • 5.2.3 Oral Antidiabetic Drugs
    • 5.2.3.1 Major Suppliers
• 5.3 Trends
• 5.4 Main National Markets
  • 5.4.1 Belgium
  • 5.4.2 Denmark
  • 5.4.3 France
  • 5.4.4 Germany
  • 5.4.5 Italy
  • 5.4.6 Japan
  • 5.4.7 Netherlands
  • 5.4.8 Norway
  • 5.4.9 Spain
  • 5.4.10 Sweden
  • 5.4.11 United Kingdom
• 6.1.5.4.12 USA

SECTION 6: COMPANY PROFILES

• 6.1 Leading Companies
  • 6.1.1 Abbott Laboratories
    • 6.1.1.1 Overview
    • 6.1.1.2 Diabetes Products
    • 6.1.1.3 Pipeline
    • 6.1.1.4 Financials
  • 6.1.2 Bayer
    • 6.1.2.1 Overview
    • 6.1.2.2 Diabetes Products
      • 6.1.2.2.1 Ascensia Blood Glucose Monitoring
    • 6.1.2.3 Financials
  • 6.1.3 Becton Dickinson
    • 6.1.3.1 Overview
    • 6.1.3.2 Diabetes Products
      • 6.1.3.2.1 Insulin Injection Devices
      • 6.1.3.2.2 Glucose Monitoring Products
      • 6.1.3.3 Financials
  • 6.1.4 Bristol-Myers Squibb
    • 6.1.4.1 Overview
      • 6.1.4.1.1 Problems with Generics
    • 6.1.4.2 Diabetes Products
    • 6.1.4.3 Financials
  • 6.1.5 Eli Lilly
    • 6.1.5.1 Overview
    • 6.1.5.2 Diabetes Products
    • 6.1.5.3 Financials
    • 6.1.5.4 Pipeline
  • 6.1.6 Glaxo SmithKline
    • 6.1.6.1 Overview
    • 6.1.6.2 Diabetes products
    • 6.1.6.3 Financials
    • 6.1.6.4 Pipeline
  • 6.1.7 Johnson & Johnson
    • 6.1.7.1 Overview
    • 6.1.7.2 Diabetes Products
    • 6.1.7.3 Financials
  • 6.1.8 Medtronic
    • 6.1.8.1 Overview
    • 6.1.8.2 Diabetes Products
      • 6.1.8.2.1 Paradigm 512/712 insulin pump
      • 6.1.8.2.2 Paradigm 515/715 insulin pump
      • 6.1.8.2.3 CGMS System Gold
    • 6.1.8.3 Financials
    • 6.1.8.4 Pipeline
  • 6.1.9 Merck KgaA
    • 6.1.9.1 Overview
    • 6.1.9.2 Diabetes Product
    • 6.1.9.3 Financials
  • 6.1.10 Novartis
    • 6.1.10.1 Overview
    • 6.1.10.2 Diabetes Product
    • 6.1.10.3 Financials
    • 6.1.10.4 Pipeline
  • 6.1.11 Novo Nordisk
    • 6.1.11.1 Overview
    • 6.1.11.2 Diabetes Products
      • 6.1.11.2.1 Pharmaceuticals
    • 6.1.11.3 Financials
    • 6.1.11.4 Pipeline
  • 6.1.12 Pfizer
    • 6.1.12.1 Overview
    • 6.1.12.2 Diabetes Products
    • 6.1.12.3 Financials
    • 6.1.12.4 Pipeline
  • 6.1.13 Roche
    • 6.1.13.1 Overview
    • 6.1.13.2 Diabetes Products
      • 6.1.13.2.1 Accutrend GC/GCT
    • 6.1.13.3 Financials
    • 6.1.13.4 Pipeline
  • 6.1.14 Sanofi-Aventis
    • 6.1.14.1 Overview
    • 6.1.14.2 Diabetes Products
    • 6.1.14.3 Financials
    • 6.1.14.4 Pipeline
  • 6.1.15 Takeda
    • 6.1.15.1 Overview
    • 6.1.15.2 Diabetes Products
    • 6.1.15.3 Financials
    • 6.1.15.4 Pipeline
      • 6.1.15.4.1 TAK-559
      • 6.1.15.4.2 TAK-654
• 6.2 Other Companies
  • 6.2.1 77 Elektronica
  • 6.2.2 Acon Laboratories
  • 6.2.3 Activa
  • 6.2.4 AdipoGenix
  • 6.2.5 AgaMatrix
  • 6.2.6 AiMedics Pty Ltd
  • 6.2.7 Alkermes Inc.
  • 6.2.8 Amylin
  • 6.2.9 Animas Corp.
  • 6.2.10 Antares Pharma
  • 6.2.11 Apex Biotechnology Ltd
  • 6.2.12 Aradigm
  • 6.2.13 Arena Pharmaceuticals
  • 6.2.14 B Braun
  • 6.2.15 Belbiosens
  • 6.2.16 Benitec Limited
  • 6.2.17 Biocon
  • 6.2.18 Bioject Medical Technologies Inc.
  • 6.2.19 BioSafe Medical Technologies Inc
  • 6.2.20 Biovitrum
  • 6.2.21 Cell Robotics International, Inc
  • 6.2.22 ChemGenex Pharmaceuticals Ltd
  • 6.2.23 Dana Diabecare USA
  • 6.2.24 Devgen NV
  • 6.2.25 Dexcom Inc
  • 6.2.26 Diabetes Technologies Inc.
  • 6.2.27 Diagnostic Devices Inc.
  • 6.2.28 Diosynth
  • 6.2.29 EnGene
  • 6.2.30 Equidyne Corporation
  • 6.2.31 Eumed Biotechnology Co. Inc
  • 6.2.32 FivePrime Therapeutics
  • 6.2.33 FlexSite Diagnostics
  • 6.2.34 Fluent Biomedical Inc
  • 6.2.35 GlucoLight Corporation
  • 6.2.36 Glucon Medical Ltd
  • 6.2.37 Glucoplus Inc
  • 6.2.38 GluMetrics LLC
  • 6.2.39 Hemocue AB
  • 6.2.40 Hitachi Ltd
  • 6.2.41 HMD Biomedical
  • 6.2.42 Home Diagnostics Inc
  • 6.2.43 HypoGuard
  • 6.2.44 Infratec Inc
  • 6.2.45 InLight Solutions Inc
  • 6.2.46 Integrity Applications Ltd
  • 6.2.47 Kumetrix Inc
  • 6.2.48 Laboratorios Beta
  • 6.2.49 LifeTrac Systems Inc
  • 6.2.50 Ligand Pharmaceuticals Inc
  • 6.2.51 MannKind
  • 6.2.52 Menarini
  • 6.2.53 Metabolex
  • 6.2.54 Metrika Inc.
  • 6.2.55 Nektar Therapeutics
  • 6.2.56 Nipro Diabetes Systems Inc
  • 6.2.57 Owen Mumford
  • 6.2.58 Palco Laboratories
  • 6.2.59 Pelikan Technologies
  • 6.2.60 Pindi Products
  • 6.2.61 Polymer Technology Systems Inc
  • 6.2.62 Provalis plc
  • 6.2.63 QuestStar Medical Inc
  • 6.2.64 Quotient Diagnostics Ltd
  • 6.2.65 Rosch AG Medizintechnik
  • 6.2.66 Sanwa Kagaku Kenkyusho Co. Ltd.
  • 6.2.67 SenSys Medical
  • 6.2.68 Laboratoires Servier
  • 6.2.69 Sirna Therapeutics
  • 6.2.70 Smiths Medical
  • 6.2.71 Sontra Medical Corporation
  • 6.2.72 SpectRx Inc
  • 6.2.73 TaiDoc Technology Corporation
  • 6.2.74 Terumo Medical Corporation
  • 6.2.75 Theratechnologies Inc.
  • 6.2.76 TolerRx Inc.
  • 6.2.77 US Diagnostics Inc
  • 6.2.78 Vaxine Pty Ltd.
  • 6.2.79 VeraLight Inc.
  • 6.2.80 Vivo Medical Inc.
  • 6.2.81 Wockhardt Ltd

List of Exhibits

• Exhibit ES-1: Total Diabetes Market, 2004
• Exhibit ES-2: Regional Segmentation of Diabetes Market
• Exhibit 1.1: Threshold Glucose Levels Indicative of Diabetes/Hyperglycemia (mmol/L)
• Exhibit 1-2: Main Brands and Types of Insulin
• Exhibit 1-3: Oral Diabetes Treatments
• Exhibit 1-4: Prevalence of Diabetes by Region (Age 20-79 Years)
• Exhibit 1-5: Differences in the Prevalence of Type 2 Diabetes Among Selected Ethnic Groups, 2003
• Exhibit 1-6: Prevalence of Diabetes in USA, 2003
• Exhibit 1-7: Incidence of Type 1 Diabetes in Western European countries (Cases per 100,000 Child Population, per Annum)
• Exhibit 1-8: Type 1 Diabetes Incidence Growth Rates in Selected European Countries
• Exhibit 1-8: Estimated Prevalence of Type 2 Diabetes in Western European Countries
• Exhibit 2-1: International Suppliers of Blood Lancets
• Exhibit 2-2: Blood Glucose Meters
• Exhibit 2-3: Research Projects in Glucose Monitoring
• Exhibit 2-4: Commercial Software Programs for Windows and Macintosh
• Exhibit 3-1: Major Brands of Insulin
• Exhibit 3-2: Manufacturers of Insulin Pens
• Exhibit 3-3: Manufacturers of Insulin Pups
• Exhibit 3-4: Sulfonylureas
• Exhibit 3-5: Oral Hypoglycemics
• Exhibit 5-1: Prevalence of Diabetes Mellitus, by Selected Country, 2003 and 2025 (Percent of Population Age 20-79)
• Exhibit 5-2: Global Diabetes Market 2004
• Exhibit 5-3: Relative Market Size of Major Regional Diabetes Markets; USA, Western Europe and Japan
• Exhibit 5-4: Glucose Monitors: Leading Companies 2004
• Exhibit 5-5: Market for Insulin and Other Diabetes Medications, Belgium, 2003-2015
• Exhibit 5-6: Market for Glucose Meters, Belgium, 2003-2015
• Exhibit 5-7: Market for Insulin Pumps, Belgium, 2003-2015
• Exhibit 5-8: Market for Insulin and Other Diabetes Medications, Denmark, 2003-2015
• Exhibit 5-9: Market for Glucose Meters, Denmark, 2003-2015
• Exhibit 5-10: Market for Insulin and Other Diabetes Medications, France, 2003-2015
• Exhibit 5-11: Market for Glucose Meters, France, 2003-2015
• Exhibit 5-12: Market for Insulin Pumps, France, 2003-2015
• Exhibit 5-13: Market for Insulin and Other Diabetes Medications, Germany, 2003-2015
• Exhibit 5-14: Market for Glucose Meters, Germany, 2003-2015
• Exhibit 5-15: Market for Insulin Pumps, Germany, 2003-2015
• Exhibit 5-16: Market for Insulin and Other Diabetes Medications, Italy, 2003-2015
• Exhibit 5-17: Market for Glucose Meters, Italy, 2003-2015
• Exhibit 5-18: Market for Insulin Pumps, Italy, 2003-2015
• Exhibit 5-19: Market for Insulin and Other Diabetes Medications, Japan, 2003-2015
• Exhibit 5-20: Market for Glucose Meters, Japan, 2003-2015
• Exhibit 5-21: Market for Insulin Pumps, Japan, 2003-2015
• Exhibit 5-22: Market for Insulin and Other Diabetes Medications, Netherlands, 2003-2015
• Exhibit 5-23: Market for Glucose Meters, Netherlands, 2003-2015
• Exhibit 5-24: Market for Insulin Pumps, Netherlands, 2003-2015
• Exhibit 5-25: Market for Insulin and Other Diabetes Medications, Norway, 2003-2015
• Exhibit 5-26: Market for Glucose Meters, Norway, 2003-2015
• Exhibit 5-27: Market for Insulin Pumps, Norway, 2003-2015
• Exhibit 5-28: Market for Insulin and Other Diabetes Medications, Spain, 2003-2015
• Exhibit 5-29: Market for Glucose Meters, Spain, 2003-2015
• Exhibit 5-30: Market for Insulin Pumps, Spain, 2003-2015
• Exhibit 5-31: Market for Insulin and Other Diabetes Medications, Sweden, 2003-2015
• Exhibit 5-32: Market for Glucose Meters, Sweden, 2003-2015
• Exhibit 5-33: Market for Insulin Pumps, Sweden, 2003-2015
• Exhibit 5-34: Market for Insulin and Other Diabetes Medications, United Kingdom, 2003-2015
• Exhibit 5-35: Market for Glucose Meters, United Kingdom, 2003-2015
• Exhibit 5-36: Market for Insulin Pumps, United Kingdom, 2003-2015
• Exhibit 5-37: Market for Insulin and Other Diabetes Medications, United States, 2003-2015
• Exhibit 5-38: Market for Glucose Meters, United States, 2003-2015
• Exhibit 5-39: Market for Insulin Pumps, United States, 2003-2015
• Exhibit 6-1: Abbott Laboratories Financial Data, 2004
• Exhibit 6-2: Bayer Group Financials, 2004
• Exhibit 6-3: Becton Dickinson Financials, 2004
• Exhibit 6-4: Bristol-Myers Squibb Financials, 2004
• Exhibit 6-5: Eli Lilly Financials, 2004
• Exhibit 6-6: Glaxo SmithKline Financials, 2004
• Exhibit 6-7: Glaxo SmithKline Diabetes Products in Research Pipeline
• Exhibit 6-8: J&J Medical Devices and Diagnostics Financials, 2004
• Exhibit 6-9: Medtronic Financials, 2004
• Exhibit 6-10: Merck KGaA Financials, 2004
• Exhibit 6-11: Novartis Financials, 2004
• Exhibit 6-12: Novo Nordisk Financials, 2004
• Exhibit 6-13: Pfizer leading products
• Exhibit 6-14: Pfizer Financials, 2004
• Exhibit 6-15: Roche Financials, 2004
• Exhibit 6-16: Sanofi Aventis, Leading Products 2004
• Exhibit 6-17: Sanofi-Aventis Financials, 2004
• Exhibit 6-18: Takeda Leading Products
• Exhibit 6-19: Takeda Financials, 2005